Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.17 USD | +5.32% | +37.45% | +48.49% |
May. 02 | NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue | MT |
May. 02 | BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg | MT |
Financials (USD)
Sales 2024 * | 551M | Sales 2025 * | 587M | Capitalization | 2.39B |
---|---|---|---|---|---|
Net income 2024 * | -174M | Net income 2025 * | -193M | EV / Sales 2024 * | 3.94 x |
Net cash position 2024 * | 212M | Net Debt 2025 * | 234M | EV / Sales 2025 * | 4.46 x |
P/E ratio 2024 * |
-13.9
x | P/E ratio 2025 * |
-12.6
x | Employees | 1,453 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.74% |
Latest transcript on NovoCure Limited
1 day | +5.32% | ||
1 week | +37.45% | ||
Current month | +81.13% | ||
1 month | +77.93% | ||
3 months | +37.36% | ||
6 months | +87.40% | ||
Current year | +48.49% |
Managers | Title | Age | Since |
---|---|---|---|
Asaf Danziger
CEO | Chief Executive Officer | 56 | 01-12-31 |
Ashley Cordova
DFI | Director of Finance/CFO | 45 | 14-05-31 |
Moshe Giladi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Doyle
CHM | Chairman | 61 | 03-12-31 |
Kin Yip Leung
BRD | Director/Board Member | 62 | 11-08-04 |
David Hung
BRD | Director/Board Member | 66 | 18-05-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.81% | 0 M€ | 0.00% | - | |
0.71% | 0 M€ | 0.00% | - | |
0.19% | 17 M€ | +7.73% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 22.17 | +5.32% | 1,633,139 |
24-05-15 | 21.05 | +3.59% | 2,170,581 |
24-05-14 | 20.32 | +13.01% | 2,752,228 |
24-05-13 | 17.98 | +9.17% | 1,514,092 |
24-05-10 | 16.47 | +2.11% | 821,779 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.49% | 2.39B | |
+73.64% | 12.42B | |
-19.88% | 7.81B | |
+2.90% | 6.4B | |
+13.65% | 5.45B | |
+40.00% | 5.01B | |
-15.76% | 4.84B | |
-19.78% | 4.19B | |
-28.70% | 2.69B | |
+0.25% | 2.02B |
- Stock Market
- Equities
- NVCR Stock